organization · Reporting owner
ADAR1 Partners, LP
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.ACST · Entity 7266 | 10% owner | June 28, 2024 | July 11, 2024 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | 10% owner | August 09, 2024 | August 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date June 28, 2024 · Filed July 11, 2024 · Amendment
Jointly reported with ADAR1 Capital Management, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy: ADAR1 Partners | 959,571 |
Reported balance
Holding disclosure · report date 2024-06-28 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 959,571 F1: ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners"). F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| Common Warrant (Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2028-09-25 | IndirectBy: ADAR1 Partners | Not disclosed |
Reported balance
Holding disclosure · report date 2024-06-28 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F5: Pursuant to a Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 1,268,195 of Issuer's Common Stock. F1: ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners"). F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| Pre-Paid Warrant (Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy: ADAR1 Partners | Not disclosed |
Reported balance
Holding disclosure · report date 2024-06-28 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F4: Pursuant to a Pre-Funded Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 913,631 shares of Issuer's Common Stock, exercisable until fully filled. F1: ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners"). F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners").
F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners.
F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
F4: Pursuant to a Pre-Funded Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 913,631 shares of Issuer's Common Stock, exercisable until fully filled.
F5: Pursuant to a Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 1,268,195 of Issuer's Common Stock.
PALVELLA THERAPEUTICS, INC.
Report date August 09, 2024 · Filed August 12, 2024
Jointly reported with ADAR1 Capital Management, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy: ADAR1 Partners | 129,574 |
Last balance in matching sequence
After 2024-08-12 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-09 · Purchase · Acquired 3,000 · Balance 127,331 F1: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP ("ADAR1 Partners"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 2 · 2024-08-12 · Purchase · Acquired 2,243 · Balance 129,574 F1: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP ("ADAR1 Partners"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| Common StockSEC Table I · non-derivative | IndirectBy: Spearhead Insurance Solutions IDF, LLC - Series ADAR1 | 15,067 |
Reported balance
After 2024-08-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-08-12 · Purchase · Acquired 757 · Balance 15,067 F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by Spearhead Insurance Solutions IDF, LLC - Series ADAR1 ("Spearhead"). Because of the relationship between Spearhead and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by Spearhead. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP ("ADAR1 Partners"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners.
F2: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by Spearhead Insurance Solutions IDF, LLC - Series ADAR1 ("Spearhead"). Because of the relationship between Spearhead and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by Spearhead.
F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keros Therapeutics, Inc.
Report date October 15, 2025 · Filed October 15, 2025
Jointly reported with ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, Schneeberger Daniel
Section 16 reporting ended · disclosed 2025-10-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ADAR1 Partners, LP | 0 |
Reported balance
After 2025-10-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-10-15 · Sale · Disposed 4,391,237 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| Common StockSEC Table I · non-derivative | IndirectBy ADAR1 SPVI, LP | 0 |
Reported balance
After 2025-10-15 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-10-15 · Sale · Disposed 254,669 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| Common StockSEC Table I · non-derivative | IndirectBy Spearhead Insurance Solutions IDF, LLC | 0 |
Reported balance
After 2025-10-15 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-10-15 · Sale · Disposed 743,358 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP.
F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 15, 2025 13:24 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 743,358 | $17.75 | $13,194,604.50 |
DisclosureSEC source: 0000902664-25-004411 · ownership.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 0 F1 · ownership.nature: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 13:24 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 254,669 | $17.75 | $4,520,374.75 |
DisclosureSEC source: 0000902664-25-004411 · ownership.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 SPVI, LP Disclosed balance after: 0 F1 · ownership.nature: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 13:24 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,391,237 | $17.75 | $77,944,456.75 |
DisclosureSEC source: 0000902664-25-004411 · ownership.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 F1 · ownership.nature: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (right to sell) · Derivative | 2 | $0.00 Strike: $70.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 6 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 0 Underlying: Common Stock · 200 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (right to sell) · Derivative | 14 | $0.00 Strike: $70.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 5 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 1,400 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (right to sell) · Derivative | 1 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 4 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 200 | $70.00 | $14,000.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 743,358 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 1,400 | $70.00 | $98,000.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,391,237 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 100 | $60.00 | $6,000.00 |
DisclosureSEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,392,637 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 16, 2025 Filed Jun 12, 2025 16:51 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (obligation to buy) · Derivative | 178 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 0 Underlying: Common Stock · 17,800 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 16, 2025 Filed Jun 12, 2025 16:51 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (obligation to buy) · Derivative | 836 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 83,600 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 16, 2025 Filed Jun 12, 2025 16:51 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherPut Option (obligation to buy) · Derivative | 300 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCash Settled Total Return Swaps · Derivative | 74,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 9 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 50,000 Underlying: Common Stock · 74,333 shares Expires not disclosed F7 · derivative.exercise_price: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · kind: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · shares: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · price: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.exercise_date: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.expiration_date: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.underlying_shares: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · balance_after: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCash-Settled Total Return Swaps · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 8 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 124,333 Underlying: Common Stock · 500,000 shares Expires not disclosed F6 · derivative.exercise_price: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · kind: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · shares: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · price: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.exercise_date: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.expiration_date: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.underlying_shares: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · balance_after: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCash-Settled Total Return Swaps · Derivative | 325,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 7 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 624,333 Underlying: Common Stock · 325,000 shares Expires not disclosed F5 · derivative.exercise_price: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · kind: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · shares: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · price: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.exercise_date: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.expiration_date: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.underlying_shares: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · balance_after: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 74,333 | $10.33 | $767,859.89 |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 5 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,392,737 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 500,000 | $10.33 | $5,165,000.00 |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 4 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,318,404 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 325,000 | $9.86 | $3,203,525.00 |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 3,818,404 F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $10.60, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 16,365 | $9.40 | $153,752.45 |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 743,558 F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:57 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 18,560 | $9.40 | $174,374.91 |
DisclosureSEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 3,493,404 F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 22:48 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 757 | $15.88 | $12,022.98 |
DisclosureSEC source: 0001940272-24-000006 · primary_doc.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: Spearhead Insurance Solutions IDF, LLC - Series ADAR1 Disclosed balance after: 15,067 F2 · ownership.nature: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by Spearhead Insurance Solutions IDF, LLC - Series ADAR1 ("Spearhead"). Because of the relationship between Spearhead and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by Spearhead. F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 22:48 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 2,243 | $15.88 | $35,624.22 |
DisclosureSEC source: 0001940272-24-000006 · primary_doc.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: ADAR1 Partners Disclosed balance after: 129,574 F1 · ownership.nature: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP ("ADAR1 Partners"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 22:48 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 3,000 | $14.89 | $44,678.70 |
DisclosureSEC source: 0001940272-24-000006 · primary_doc.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: ADAR1 Partners Disclosed balance after: 127,331 F1 · ownership.nature: ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP ("ADAR1 Partners"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners. F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.